CSL Limited Stock price

Equities

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
287.9 AUD +0.55% Intraday chart for CSL Limited +3.25% +0.44%
Sales 2024 * 14.72B 22.63B Sales 2025 * 15.98B 24.57B Capitalization 90.27B 139B
Net income 2024 * 2.71B 4.17B Net income 2025 * 3.29B 5.06B EV / Sales 2024 * 6.8 x
Net Debt 2024 * 9.83B 15.11B Net Debt 2025 * 8.61B 13.23B EV / Sales 2025 * 6.19 x
P/E ratio 2024 *
33 x
P/E ratio 2025 *
27.2 x
Employees 32,065
Yield 2024 *
1.42%
Yield 2025 *
1.67%
Free-Float 99.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.55%
1 week+4.21%
Current month+0.59%
1 month+0.81%
3 months+0.44%
6 months+14.24%
Current year+0.44%
More quotes
1 week
276.00
Extreme 276
289.76
1 month
275.00
Extreme 275
289.76
Current year
275.00
Extreme 275
306.42
1 year
228.65
Extreme 228.65
312.99
3 years
228.65
Extreme 228.65
319.78
5 years
189.14
Extreme 189.14
342.75
10 years
63.77
Extreme 63.77
342.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-05-31
Director of Finance/CFO 59 20-09-30
Chief Tech/Sci/R&D Officer 62 20-09-30
Members of the board TitleAgeSince
Director/Board Member 69 19-12-08
President 68 90-06-30
Director/Board Member 61 21-08-18
More insiders
Date Price Change Volume
24-03-28 287.9 +0.55% 638 665
24-03-27 286.4 +1.37% 484,437
24-03-26 282.5 -0.43% 383,975
24-03-25 283.7 +0.98% 581,262
24-03-22 280.9 +1.68% 1,380,370

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
CSL Limited (CSL) is an Australia-based biotechnology company. The Company's areas of focus and exploration include rare and serious diseases, influenza vaccines, plasma collection, and therapies for iron deficiency and nephrology. The Company's segments include CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment manufactures, markets, and distributes plasma therapies (plasma products and recombinants). CSL Seqirus segment manufactures, markets, and distributes primarily influenza-related products and provides pandemic services to governments. The Company's CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency, dialysis and nephrology and rare diseases. The Company's geographical areas of operation include Australia, the United States of America, Germany, the United Kingdom, Switzerland, and China. CSL's products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
186.8 USD
Average target price
197.8 USD
Spread / Average Target
+5.86%
Consensus
  1. Stock
  2. Equities
  3. Stock CSL Limited - Australian S.E.